Abstract
Oxaliplatin is one of the most widely used anticancer drugs representing the cornerstone of the treatment of colorectal cancer. Yet a number of side effects, including oxaliplatin- induced peripheral neurotoxicity (OIPN) which represents a dose-limiting side effect in the clinical use of oxaliplatin, limit its use and a better understanding of its pathogenesis would offer a great opportunity to improve the “quality of survival” of cancer patients. So far, no treatment able to prevent or limit OIPN has been approved, and one of the reasons for this unmet clinical need is the incomplete knowledge of its pathogenesis preventing the development of rationalebased pharmacological interventions.
Preclinical and clinical evidence raised the hypothesis that intracellular calcium-related events might play an important role in the onset of OIPN. Yet, the results of mechanistic pre-clinical studies appear inconsistent and, therefore, their relevance in neuroprotective drugs design is still uncertain. Indeed, it is at present unclear whether aberrant calcium signalling is the key pathogenetic moment or whether it just constitutes the mediator of the clinical phenotype.
This review will summarize the preclinical results involving calcium-related events and OIPN with the aim to provide an updated overview of the available evidence and highlight the most promising strategies to design effective neuroprotective drugs. In particular, we will focus on the pre-clinical evidence suggesting that TRPV1, TRPM8 or TRPA1 might be involved, as these appear particularly amenable to pharmacological modulation.
Keywords: Oxaliplatin, calcium, neurotoxicity, pathogenesis, therapy, preclinical, in vitro.
Current Medicinal Chemistry
Title:Calcium-related Neurotoxicity of Oxaliplatin: Understanding the Mechanisms to Drive Therapy
Volume: 22 Issue: 32
Author(s): Paola Marmiroli, Guido Cavaletti, Valentina Carozzi, Beatrice Riva, Dmitry Lim and Armando A. Genazzani
Affiliation:
Keywords: Oxaliplatin, calcium, neurotoxicity, pathogenesis, therapy, preclinical, in vitro.
Abstract: Oxaliplatin is one of the most widely used anticancer drugs representing the cornerstone of the treatment of colorectal cancer. Yet a number of side effects, including oxaliplatin- induced peripheral neurotoxicity (OIPN) which represents a dose-limiting side effect in the clinical use of oxaliplatin, limit its use and a better understanding of its pathogenesis would offer a great opportunity to improve the “quality of survival” of cancer patients. So far, no treatment able to prevent or limit OIPN has been approved, and one of the reasons for this unmet clinical need is the incomplete knowledge of its pathogenesis preventing the development of rationalebased pharmacological interventions.
Preclinical and clinical evidence raised the hypothesis that intracellular calcium-related events might play an important role in the onset of OIPN. Yet, the results of mechanistic pre-clinical studies appear inconsistent and, therefore, their relevance in neuroprotective drugs design is still uncertain. Indeed, it is at present unclear whether aberrant calcium signalling is the key pathogenetic moment or whether it just constitutes the mediator of the clinical phenotype.
This review will summarize the preclinical results involving calcium-related events and OIPN with the aim to provide an updated overview of the available evidence and highlight the most promising strategies to design effective neuroprotective drugs. In particular, we will focus on the pre-clinical evidence suggesting that TRPV1, TRPM8 or TRPA1 might be involved, as these appear particularly amenable to pharmacological modulation.
Export Options
About this article
Cite this article as:
Marmiroli Paola, Cavaletti Guido, Carozzi Valentina, Riva Beatrice, Lim Dmitry and Genazzani A. Armando, Calcium-related Neurotoxicity of Oxaliplatin: Understanding the Mechanisms to Drive Therapy, Current Medicinal Chemistry 2015; 22 (32) . https://dx.doi.org/10.2174/0929867322666151001121302
DOI https://dx.doi.org/10.2174/0929867322666151001121302 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting c-MET/HGF Signaling Pathway in Upper Gastrointestinal Cancers: Rationale and Progress
Current Drug Targets From Laptop to Benchtop to Bedside: Structure-based Drug Design on Protein Targets
Current Pharmaceutical Design The Renin-angiotensin System as a Target of Novel Anticancer Therapy
Current Pharmaceutical Design Cancer Biomarker Discovery for Precision Medicine: New Progress
Current Medicinal Chemistry Contribution of Dietary Factors to Peroxisome Proliferator-Activated Receptor-Mediated Inflammatory Signaling in Arthritic Diseases
Current Rheumatology Reviews Cannabinoid 1 (CB1) Receptor - Pharmacology, Role in Pain and Recent Developments in Emerging CB1 Agonists
CNS & Neurological Disorders - Drug Targets The Therapeutic Potential of Targeting Hsp90-Cdc37 Interactions in Several Diseases
Current Drug Targets Dual Function of Nitric Oxide in Carcinogenesis, Reappraisal
Current Drug Metabolism Nucleosome Positioning Based on the Sequence Word Composition
Protein & Peptide Letters Etodolac Enhances the Radiosensitivity of Irradiated HT-29 Human Colorectal Cancer Cells
Current Radiopharmaceuticals Current Targets for Anticancer Drug Discovery
Current Drug Targets Status of α-emitter Radioimmunoconjugates for Targeted Therapy
Current Radiopharmaceuticals Targeting Heat Shock Proteins in Prostate Cancer
Current Medicinal Chemistry Prediction of Linear B-Cell Epitopes with mRMR Feature Selection and Analysis
Current Bioinformatics Telomerase and Survivin in Colorectal and Pancreatic Cancer – Biomarkers of Life and Death in the Balance Between Proliferation and Apoptosis
Current Cancer Therapy Reviews The Versatile Stress Protein Mortalin as a Chaperone Therapeutic Agent
Protein & Peptide Letters Dysregulated Post-Transcriptional Control of COX-2 Gene Expression in Cancer
Current Pharmaceutical Design Current Opinion on 3-[2-[(2-Tert-Butyl-Phenylaminooxalyl)-Amino]-Propionylamino]- 4-Oxo-5-(2,3,5,6-Tetrafluoro-Phenoxy)-Pentanoic Acid, an Investigational Drug Targeting Caspases and Caspase-Like Proteases: The Clinical Trials in Sight and Recent Anti-Inflammatory Advances
Recent Patents on Inflammation & Allergy Drug Discovery Patent Selections
Recent Patents on DNA & Gene Sequences Panobinostat: The Small Molecule Metalloenzyme Inhibitor with Marvelous Anticancer Activity
Current Topics in Medicinal Chemistry